⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
Form 8-K
sec.gov
OSTX
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
globenewswire.com
ATOS
ONCY
SNSE
TNGX
OSTX
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K
sec.gov
OSTX
OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX